Development of small molecule inhibitors of the E3 ligase NEDD4

Active Project Grant Awarded Last action

Award ID
F32GM159396
Recipient
Awarding agency
Obligated
$230,388

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date 25% complete
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded Brigham & Women's Hospital Inc. $230,388 on March 12, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop small molecule inhibitors of the E3 ligase NEDD4.

The project consists of two research aims. Aim 1 investigates the structural dynamics of the NEDD4 HECT domain through NMR spectroscopy, using different labeling techniques and pulse sequences to obtain and assign an NMR spectrum, then studying conformational changes of the HECT domain during the ubiquitination process by incubating it with different protein partners and obtaining corresponding spectra. The kinetics of these conformational changes and conformational state preferences will be determined using relaxation, saturation, and exchange NMR experiments. Aim 2 develops small molecule inhibitors of NEDD4 and evaluates their efficacy in cancer cell lines through structure-activity relationship studies on a molecule identified in an in silico screen, with analogues evaluated in plate-based high-throughput assays. The selected inhibitor will be validated and characterized to determine binding site and mechanism of inhibition, then tested in various cancer cell lines.

Performance occurs in Boston, Massachusetts. The award covers the period from March 12, 2026, through September 14, 2028. This is assistance type Project Grant.

Description

Abstract
Ubiquitination is a post-translational modification responsible for maintaining protein homeostasis within the cell. The hect E3 ligases are a family of enzymes that catalyze ubiquitination, and dysregulation of this family of proteins is responsible for the pathogenesis of many diseases. In particular, the E3 ligase NEDD4 has been implicated in neurodegenerative disease, cardiovascular disease, and cancer. Despite the implication of NEDD4 in many diseases, studies of this E3 ligase have been hindered by a limited understanding of the structural dynamics of the hect domain, which catalyzes ubiquitination, and the lack of selective small molecule probes. This proposal aims to elucidate the conformational dynamics of the NEDD4 hect domain and use this information to develop small molecule inhibitors of NEDD4. Aim 1 will investigate the structural dynamics of the hect domain. An NMR spectrum of the NEDD4 hect domain will be obtained and assigned using different labeling techniques and NMR pulse sequences. Next, this assigned spectrum will be used to study the conformational changes of the hect domain in different steps of the ubiquitination process by incubating the hect domain with different protein partners and obtaining corresponding spectra. Finally, the kinetics of these conformational changes and the preference for each conformational state will be determined using a series of relaxation, saturation, and exchange NMR experiments. Aim 2 will afford small molecule inhibitors of NEDD4 and evaluate their efficacy in various cancer cell lines. Structure-activity relationship studies will be performed on a molecule previously identified in an in silico screen and analogues will be evaluated in a plate-based high throughput assay. This inhibitor will then be validated and characterized to determine its binding site and mechanism of inhibition. Finally, this inhibitor will be tested in various cancer cell lines in which NEDD4 has been identified to contribute to the promotion of cell proliferative activity. This proposal will deepen the understanding of the conformational changes the NEDD4 hect domain undergoes to ubiquitinate its substrates and afford a small molecule inhibitor that can be used as a probe to understand the potential of NEDD4 as a therapeutic target. This proposal will be performed at brigham and women's hospital, harvard medical school, and dana-farber cancer institute all of which have the resources necessary to support this research. These institutions provide a collaborative, interdisciplinary environment critical to the success of this project. This proposal will also equip the applicant with new skills in protein engineering, enzymology, and protein NMR, preparing him for an independent academic career in the field of chemical biology. In addition to acquiring new technical skills, the applicant will develop his oral and written communication skills through manuscript preparation, grant writing, and presentations of his findings in departmental seminars and national conferences. He will also continue to teach and mentor undergraduate and graduate students affording him the necessary mentorship skills needed in academia.

Transactions

Action Obligated Date
Amendment $79,348
Amendment $75,520
Amendment $0
Original award $75,520

Quick answers

Who received award F32GM159396?

F32GM159396 was awarded to Brigham & Womens Hospital Inc. by National Institute of General Medical Sciences (National Institutes of Health) on March 12, 2026.

How much is award F32GM159396 worth?

$230,388 has been obligated on F32GM159396.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award